NCT07780669
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 7 → 11 locations
- Minor Study sites: 7 to 9
- Notable Eligibility criteria expanded, about 17 words
- Trial sites expanded: 2 → 7 locations
- Secondary endpoints: details revised at 2 of 5 entries
- Notable Recruitment opened
- Study sites: 0 to 2
- Start date changed from estimate of Aug 31, 2026 to Aug 27, 2026
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Annualized rate of moderate or severe COPD Exacerbations
Timeframe: Up to Week 78
Secondary (5)
Change from Baseline in St. George's respiratory questionnaire (SGRQ) total score
Change from Baseline in pre-Bronchodilator Forced expiratory volume in 1 second (FEV1)
Annualized rate of COPD exacerbations requiring emergency department (ED) visit or hospitalization
Annualized rate of moderate/severe COPD exacerbations among participants with elevated screening blood eosinophil counts (BEC)
Time to first moderate or severe COPD exacerbation
Arms and interventions
Participants receiving GSK5784283 plus standard of careExperimental
Participants receiving matching placebo plus standard of carePlacebo comparator
Drugs: GSK5784283, Placebo, Standard of care
Sites
11 sites in 2 countries
United States 7, Japan 4